News | April 02, 2015

World Molecular Imaging Society, National Cancer Institute Collaborating Expansion of Co-Clinical Trials

Partnership will look to speed the discovery of more and better treatments for cancer and other diseases

April 2, 2015 — The World Molecular Imaging Society (WMIS) announced the kick-off of a collaboration with the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), to promote best practices for co-clinical trials. The end goal of the collaboration is to speed the discovery of more and better treatments for cancer and other diseases. 

WMIS also lauded President Obama's recent announcement of the Precision Medicine Initiative designed "to bring us closer to curing diseases like cancer and diabetes?—?and to give all of us access to the personalized information we need to keep ourselves and our families healthier," stated Jason Lewis, M.D, professor and vice chair for research, Emily Tow Jackson Chair at Memorial Sloan Kettering Cancer Center, and president of the WMIS.

Over the past two years, WMIS and the American Association of Physicists in Medicine (AAPM) have shared their interest with NCI to promote best practices for co-clinical trials. The two groups met at the World Molecular Imaging Congress in September 2014 to finalize an agreement that WMIS, with the assistance of the AAPM, would explore how to promote best practice for quantitative imaging for co-clinical trials.

Co-clinical trials are defined as parallel or sequential trials of combination therapy in patients and in mouse and human-in-mouse models of appropriate genotypes to represent the patients. The initiative is designed to help establish best practices for quantitative imaging methods and imaging protocols that are applied to both mouse and human-in-mouse models. The research resources are expected to improve the correlation of results from mouse models with prospective and/or retrospective clinical trial data. The clinical goals are to support effective mouse/human co-clinic therapy and prevention trials.

"Molecular imaging and the emerging field of theranostics are essential to the successful implementation of precision medicine. The World Molecular Imaging Society, with its international forum for discussing all aspects of molecular imaging and related fields, is in an unique position to take the lead in global discussion, innovation and scientific collaboration, from preclinical studies to first-in-human imaging trials," said Hedvig Hricak, M.D., Ph.D., chairman, Department of Radiology, Memorial Sloan-Kettering Cancer and member of WMIS.  

As part of the agreement, WMIS will include two spotlight sessions on precision medicine and co-clinical trials during the upcoming 8th Annual World Molecular Imaging Congress. The theme of the meeting is Precision Medicine, Visualized, which embodies current and future roles of molecular imaging in basic science, translational medicine and healthcare. The WMIC meeting will take place Sept. 2-5, 2015 in Honolulu, Hawaii.

Precision medicine is an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment and lifestyle for each person. While significant advances in precision medicine have been made for select cancers, the practice is not currently in use for most diseases. Many efforts are underway to help make precision medicine the norm rather than the exception. To accelerate the pace, President Obama unveiled the Precision Medicine Initiative — a new enterprise to revolutionize medicine and generate the scientific evidence needed to move the concept of precision medicine into every day clinical practice. To be most effective and comprehensive, the Precision Medicine Initiative will engage partners across all communities—scientific, medical, health, and societal—including patients and patient advocacy organizations, academic medical centers, clinicians, scientists from multiple disciplines, pharmaceutical companies and medical product developers, scientific societies and research coalitions, privacy experts and medical ethicists.

For more information: www.wmis.org

Related Content

Novel PET Tracer Clearly Identifies and Tracks Bacterial Lung Infection

Representative PET/CT images of 18F-FDS and 18F-FDG in inflamed mice. Mice were inoculated with dead K. pneumoniae (10^8 CFU/mL). Imaging was performed for days 1, 2, 3 and 4 using 18F-FDG and 18F-FDS. CT images showed clear inflammation on day 2 and day 3 with corresponding high 18F-FDG uptake on PET. No significant uptake of 18F-FDS was detected for any of those 4 days. Credit: J Li et al., University of Louisville School of Medicine, Louisville, Ky.

News | PET-CT | January 22, 2018
January 22, 2018 — Researchers at the University of Louisville, Kentucky, have demonstrated that a new...
PET Tracer Gauges Effectiveness of Promising Alzheimer's Treatment

Longitudinal PET imaging with 18F-AV45. PET imaging shows the average 18F-AV45 uptake per animal group at 8 and 13 months of age. A significant interaction of genotype treatment was observed in the cortex (p = 0.0248), hippocampus (p = 0.0071) and thalamus (p = 0.0084), indicating reduced [18F]-AV45 uptake in BACE1 inhibited transgenic mice. Credit: MICA, University of Antwerp, Belgium.

News | Radiopharmaceuticals and Tracers | December 28, 2017
In the December featured basic science article in The Journal of Nuclear Medicine, Belgian researchers report on the...
Vital Unveils Newest Vitrea Advanced Visualization Release at RSNA 2017
Technology | Advanced Visualization | December 04, 2017
Vital Images unveiled the newest version of Vitrea Advanced Visualization software, the cornerstone of its imaging...
Michael J. Fox Foundation and Tau Consortium Developing PET Tracers for Neurodegenerative Disease
News | Radiopharmaceuticals and Tracers | October 27, 2017
The Michael J. Fox Foundation for Parkinson's Research (MJFF) and the Tau Consortium announced a funding partnership to...
Netherlands Cancer Institute Exploring Molecular Imaging Technology for Prostate Cancer Surgery
News | Molecular Imaging | October 26, 2017
The Netherlands Cancer Institute (NKI) announced it has received funding from the Dutch Cancer Society (KWF...
SNMMI Publishes New FDG PET/CT Appropriate Use Criteria
News | PET-CT | October 25, 2017
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for FDG PET/...
Biodex Unveils Atomlab 500 Dose Calibrator and Wipe Test Counter
Technology | Nuclear Imaging | October 19, 2017
Biodex Medical Systems announced the full release of the Atomlab Dose Calibrator and Wipe Test Counter to the market...
ASNC and ASE Team Up to Expand ImageGuide Registry
News | Cardiovascular Ultrasound | October 12, 2017
The American Society of Nuclear Cardiology (ASNC) and the American Society of Echocardiography (ASE) jointly announced...
MR Solutions Showcases Multimodality MRI Solutions on Two Continents
News | Magnetic Resonance Imaging (MRI) | October 11, 2017
October 11, 2017 — MR Solutions took their cryogen-free preclinical multimodality...
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
Overlay Init